ArticleTranslational psychiatry2025
Hypothalamic functional connectivity, depressive symptoms, and post-treatment SOREMPs in narcolepsy type 1: links to sleep latency and mediation mechanisms.
Article in Translational psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Narcolepsy: immunity, neural circuitry, and brain network reconfiguration.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Narcolepsy type 1 (NT1) is characterized by sleep-onset rapid eye movement periods (SOREMPs), reflecting dysregulated rapid eye movement (REM) sleep control. Treatment response variability in SOREMP persistence remains poorly understood, particularly regarding hypothalamic functional connectivity (FC) and depressive symptoms. This study investigated clinical, polysomnographic, and neuroimaging differences between NT1 patients with low (0-1) versus high (≥2) post-treatment SOREMPs, and explored whether hypothalamic FC mediates the relationship between depressive symptoms and SOREMPs outcomes. One hundred ten NT1 patients were categorized into low (n = 62) and high (n = 48) post-treatment SOREMPs groups. Demographic, clinical variables (symptoms and questionnaires), and polysomnography (PSG)/multiple sleep latency test (MSLT) parameters were compared. Resting-state fMRI assessed hypothalamic FC with whole-brain regions. LASSO regression modeled associations between FC, sleep latency, and clinical variables, while mediation analysis tested hypothalamic pathways as mediators of depression-SOREMP relationships. High post-treatment SOREMPs patients exhibited shorter pre/post-treatment REM sleep latency, lower post-treatment wakefulness index, and higher depressive symptom prevalence compared to low SOREMPs patients. Hypothalamic FC differed significantly between groups: low SOREMPs patients showed enhanced connectivity in right medial hypothalamus-right thalamus/left precuneus, left medial hypothalamus-left inferior parietal lobule (IPL), and right lateral hypothalamus-left IPL pathways, but reduced connectivity in left lateral hypothalamus-right insula/left anterior cingulate cortex pathways (p < 0.05, GRF-corrected). LASSO regression identified left medial hypothalamus-left IPL FC as a significant predictor of post-treatment MSLT mean sleep latency (β = 0.272, p = 0.001), alongside age (β = -0.256, p = 0.002) and pre-treatment sleep latency (β = 0.392, p < 0.001). Mediation analysis revealed complete mediation by two hypothalamic pathways: depressive symptoms predicted reduced right lateral hypothalamus-left IPL FC (indirect effect: 0.15-1.05), associated with fewer SOREMPs, and increased left lateral hypothalamus-right insula FC (indirect effect: 0.08-1.14), associated with more SOREMPs. Hypothalamic-parietal/insular FC abnormalities link depressive symptoms to post-treatment SOREMP variability in NT1, with specific pathways mediating opposing effects on REM sleep regulation. These findings highlight hypothalamic connectivity as a critical neural substrate for treatment response, integrating sleep-wake and emotional processing networks. Targeting these pathways may improve personalized management for NT1 patients with comorbid depression and treatment-resistant SOREMPs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.